Search

everythinglearnresearchcommunity

for

Search:↓

A new compound shows promise as a topical treatment for hair loss.

The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.

Cancer treatments often cause skin, nail, and hair problems.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

Steroid sulfatase inhibitors could help treat hormone-related disorders and cancers.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.

Peptide-based PROTACs show promise in targeting hard-to-treat proteins, especially for cancer therapy.

Targeting SOX proteins may improve cancer treatment by restoring immune function.

Tumor immunotherapy can cause hair loss by disrupting hair follicle immunity.

Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.

Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.

Topical vasoconstrictors do not reduce chemotherapy effectiveness against leukemia in mice.

Tumor suppressors help control inflammation in cancer and restoring their function could lead to new treatments.

PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.

Chemotherapy-induced hair loss may be linked to immune system changes, and certain treatments could help but need careful use.

Targeting multiple pathways and understanding genetic mutations are crucial for effective melanoma therapy.

Newly designed proteins can effectively degrade specific proteins in cells, offering a promising alternative for targeted protein degradation.

Cyclosporin A and FK506 can start new hair growth without needing immunosuppression.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

11β-Hydroxylase inhibitors help prevent seizures in mice by boosting natural neurosteroid production.

The combination treatment showed a higher response rate but no significant survival benefits.

Protein Kinase C shows promise for cancer treatment, but more research is needed to develop effective inhibitors.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

Topical calcitriol-analogs can reduce hair loss caused by chemotherapy.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.

JAK inhibitors effectively treat skin conditions and topical forms are safer.